Batimastat injectable inhibitor of matrix metalloproteinase: Received U.K. regulatory approval to resume clinical testing of the agent. Tests had been halted du

British Biotech plc (BBIOY), Oxford, U.K. Product: Batimastat injectable inhibitor of matrix metalloproteinase Indication: Malignant ascites of abdominal cancers and pleural effusion from chest cancer...